> Genfit offloaded the Chinese rights to NASH prospect elafibranor to Terns Pharmaceuticals for $35 million (€31 million) upfront. The deal is worth up to $193 million more in milestones. Statement
> Boehringer Ingelheim made a milestone payment to Oxford BioTherapeutics after it advanced an oncology drug candidate. Release
> Vesalius Biocapital closed its third life sciences fund at €120 million. The VC shop had aimed to raise $150 million and close the fund last year. Statement
> C4X Discovery teamed up with PhoreMost to access technology to support its Parkinson’s disease drug discovery activities. Release
> Poxel and Sumitomo Dainippon posted top-line data from a phase 3 trial of imeglimin in Type 2 diabetes. The trial met its primary endpoint. Statement
> Allergy Therapeutics secured a $7.6 million settlement through litigation against Inflamax Research. The case centered on whether a phase 2 allergy trial was performed properly. Release